HistoIndex AI Analysis Confirms Strong Fibrosis Improvement in D&D Pharmatech’s Phase 2 MASH Trial This month, HistoIndex announced new data highlighting the value of AI-powered quantitative pathology in advancing MASH drug development. Using our proprietary AI algorithm, qFibrosis®, we conducted an independent analysis of liver biopsies from D&D Pharmatech’s Phase 2 trial of zabopegdutide (DD01) – […]
Newsletter May and June 2026 Read More »
AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial SINGAPORE and SEOUL, South Korea, June 17, 2026 /PRNewswire/ — HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech, today announced positive results from HistoIndex’s AI-based quantitative analysis of liver biopsy samples from the
Clinical Spotlight is a HistoIndex newsletter series that explores topics in MASH, clinical diagnostics, and chronic liver disease management. Each edition provides commentary based on evidence from relevant publications and the latest research developments. The emergence of FDA-approved treatments for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis (F2–F3) marks an important milestone in hepatology. However,
April Highlights Driving Momentum Through New Strategic Partnerships in Texas and California The past month, we continued to build momentum, expanding access to advanced quantitative diagnostics across the U.S. through new partnerships with Houston Research Institute (HRI) Kingwood in Texas and Knowledge Research Center (KRC) in Orange, California. HRI Kingwood is a new addition to
Newsletter April 2026 Read More »
HistoIndex Extends Access To Its MASH Diagnostic Offering Through New Partnerships In Texas And California SINGAPORE, April 28, 2026 /PRNewswire/ — HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced the continued expansion of its commercial partnership network in the United States with the addition of two new hepatology and gastroenterology centers
March Highlights qFibrosis® Revealing New Insights into Treatment Response with Resmetirom in the MAESTRO-NASH Phase 3 Study qFibrosis® once again takes center stage in advancing our understanding of fibrosis in MASH. A recent Journal of Hepatology publication, “Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH Phase III clinical trial,” highlights how
Newsletter March 2026 Read More »
As Metabolic Dysfunction-associated Steatohepatitis (MASH) continues to rise in both clinical prevalence and therapeutic focus, the demand for accurate, reproducible, and scalable fibrosis assessment has intensified. Fibrosis remains the most critical histological feature for staging disease severity, predicting outcomes, and evaluating treatment response. Traditionally, liver biopsy evaluation has relied on expert interpretation, an approach that,
February Highlights qFibrosis® Uncovers Divergent Collagen Remodeling Across Liver Disease Subtypes A recent study conducted by Seoul National University Boramae Medical Center and Kyung Hee University Hospital provides new insights into fibrosis progression across steatotic liver disease subtypes. Now published in Gastroenterology, the study utilized HistoIndex’s fibrosis quantification algorithm, qFibrosis®, to identify distinct patterns of
Newsletter February 2026 Read More »
Advancing MASH Diagnostics Through Strategic Partnerships January 20, 2026 – HistoIndex is set to expand its footprint in clinical hepatology and gastroenterology through new commercial partnerships with leading medical centers in the US and Europe. These collaborations unlock our unique diagnostic offering, which combines standard histopathological evaluation by expert pathologists with AI-driven biopsy analysis. Such
Newsletter January 2026 Read More »
HistoIndex Partners with Houston Research Institute to Expand Advanced MASH Diagnostic Services SINGAPORE, Jan. 21, 2026 /PRNewswire/ — HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced a strategic partnership with Houston Research Institute (HRI). HRI is a leading research institute focused on conducting clinical trials in hepatology and gastroenterology, with a